skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Sponsors

Icon
IQVIA
lachman_consultants
Medidata Logo
Skipta logo
Syneos
Worldwide Clinical Trials
Wuxi Logo
Award Categories & Entry Criteria



Best Company in an Emerging Market

Scrip’s Best Company in an Emerging Market Award seeks to reward the growing R&D-based pharmaceutical industry founded in areas beyond its traditional geographic borders of North America, Western Europe and Japan.
This Award is open to any research-based pharmaceutical or biotechnology company that has its headquarters in an emerging market.

The judges will be looking for excellent performance across a range of business activities between June 1, 2017 and May 31, 2018. This could mean anything from growing sales and profits to launching new products, or signing a transformative new deal.

Companies eligible for this Award are those based in emerging markets in Asia, central and eastern Europe, central and south America, the Middle East and Africa.

To enter this category, please answer the following:

  • Please give the name of the entering company and country where it is headquartered.
  • What has been this company’s most significant achievement during the year?
  • Give details of what this company has achieved in terms of:
    – Growth in sales and profits
    – Signing important new deals
    – Introducing new products onto the market
    – Producing a promising new drug pipeline
    – Operational improvements, particularly after restructuring, or changing the focus of the business.



Best Technological Development in Clinical Trials

The Scrip Awards for Best Technological Development in Clinical Trials recognize the promising and disruptive role that digital health technology now plays in clinical drug development. The award applauds advances that are focused on helping sponsors, and those designed to ease the experience of clinical trial participants.

This Award recognizes the vital importance of using the most sophisticated platforms to catalyze and optimize data gathered during clinical trials. Advances in software and applications have a pivotal role to play at all stages of the trial process, assisting sponsors in effective management of study logistics, monitoring, risk mitigation and timely data collection and analysis. The judges will be looking for the product or suite of products that help study teams better manage and oversee clinical trial activities.

All technologies launched or significantly updated between June 1, 2017 and May 31, 2018 are eligible to enter

Companies wishing to enter must have played a role in the development of the nominated technology, and all parties to any joint development agreements should be disclosed in the application.

To enter this category, please provide the following:

  • The name of all companies involved in the product development, including an outline of their role(s).
  • Specify the date and market of the technology’s first launch, if applicable.
  • Outline the key features and benefits of the technology, and how they support the clinical trial process or the patient experience.
  • What problems does this product solve and what is novel about it?
  • What is the single most significant benefit of the entrant’s technology to users?
  • Give an estimate of how much the technology could save a sponsor (in US$ or time) on a typical protocol compared with existing solutions.
  • If possible, please provide a link to a product demo (product webpage, YouTube video, etc.)


Community Partnership of the Year Award

This Scrip Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organization.

The judges will be looking for effective partnership activity that took place between June 1, 2017 and May 31, 2017 to the benefit of humankind. Types of partnerships could include, for example, patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.

To enter this category, please answer the following:

  • Please give the name of the entering company and the name of the partnership
  • Please outline the nature of the partnership being entered
  • What were the aims of the partnership?
  • What were the benefits of the partnership and how were they measured?
  • What lessons were learned from the partnership and how might it be improved in future?


 

Best Use of Real-World Evidence

The use of real-world evidence (RWE) is becoming increasingly important for stakeholders to understand the value of drugs in the market and not just the highly controlled environment of the clinical trial. Use of RWE helps companies respond to the fast-changing pricing and reimbursement climate, and the market changes forced by the increasing personalization of medicine. 

New for 2018, this award will focus on the best use of RWE to provide the best return on investment in R&D and transform patient care. This could include research by pharma companies and/or CROs that has demonstrated a benefit to the wider healthcare system and/or patients, or has supported the marketing of a medicinal product. 

To enter this category, please answer the following:

  • Please give the name the company or CRO entering.
  • Please give full details of the RWE study, and summarize its findings.
  • How the data have undergone peer review – presentation at a scientific conference, publication in a peer-reviewed journal, acceptance by a regulatory body, for example? 
  • How have the data been used to:
    support or confirm conventional RCT data
    impact clinical practice or 
    inform pricing and reimbursement discussions?

  

 

Best Partnership Alliance

Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs from the earliest stages.

The judges will be focusing on deals that require strong strategic input from both partners, involving business development, joint marketing/promotion or joint R&D. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure.

Partnerships must have been announced, or have achieved a significant milestone, between June 1, 2017 and May 31, 2018 and entrants should be able to show some sustained benefits from the deal. NB: Deals between majority or wholly owned subsidiaries and their parent companies are not eligible for this Award.

To enter this category, please answer the following:

  • Please give the name of company/organizations involved.
  • Please outline the structure of the partnership, detailing the parties involved, what it covers and the responsibilities on both sides.
  • Does its structure represent an innovative business model, and if so how? How does it demonstrate that either party was the "partner of choice"?
  • Please summarize the strategic potential of the deal, and if applicable the milestone reached.
  • Please explain how the deal is mutually beneficial to both parties.
  • What aspect of the deal makes it unique or particularly special?
  • How does the collaboration hope to meet any unmet medical need?

IMPORTANT NOTE Would your deal fit better into the Licensing Deal of the Year category? Please check before you enter.



Financing Deal of the Year

This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public-private partnership deals to venture fundraising and public offerings, but should be earmarked for use in drug discovery and/or development.

In making their decision, the judges will scrutinize entrants on their fundraising strategy, amount raised, the structure of the deal, and on how the money will be used. This Award is open only to companies actually raising the funds (i.e., not bankers or agents). To be eligible, all financing must have been announced between June 1, 2017 and May 31, 2018.

To enter this category, please answer the following questions:

• Please outline the form of the financing, how much money was raised (including how this compares with the company’s capital base), and how close was this to meeting your fundraising objectives?
• Please explain how this source of financing was best suited to your purposes.
• Please describe how this fundraising was particularly creative. Has this set a precedent that has since been repeated?
• Did the funding succeed in other ways, such as bringing on board a new kind of investor?
• How will the money be used?
• Please give evidence of early value creation from the deal.


 

IQVIA’S Clinical Advance of the Year Award

This Scrip Award seeks to recognize success in a clinical trial of a new drug product that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

Unlike the Best New Drug Award, the product involved need not yet be approved, but as with that award the judges will be looking for innovation, clear proof of benefit and potential commercial reward.

To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between June 1, 2017 and May 31, 2018.

Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.

To enter this category, please answer the following questions:

  • Please give full details of the study, i.e., its name (protocol ID, trial identifier), Phase, disease type and patients segment studied, sponsors, and the primary drug tested.
  • Please summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints.
  • How does the drug work in the setting tested?
  • How do these findings represent a potential leap forward in therapy, or fulfil an unmet medical need?
  • What could be the potential market size of this breakthrough?



Licensing Deal of the Year – sponsored by Worldwide Clinical Trials

Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing. (NB It does not include more involved partnerships between companies to explore particular therapeutic strategies (see criteria for the Best Partnership Alliance Award).)

In choosing the winner of Scrip’s Licensing Deal of the Year Award, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to the benefits they give to both sides. To qualify, licensing deals must have been closed between June 1, 2017 and May 31, 2018.

To enter this category, please answer the following:

  • Please outline the structure of the deal, giving the names of the parties involved, the drug candidate(s) concerned, and what rights it covers.
  • What is the monetary value of the deal in up-front and milestone payments?
  • What is the geographic spread of the deal? Does it allow any party to enter new markets?
  • What is the strategic value of the licensed product to the licensee’s business?
  • Please explain how the licensed product was the best possible candidate to complement the rest of the licensee’s pipeline or particular disease franchise.

IMPORTANT NOTE Would your entry fit better in the Best Partnership Alliance category? Please consider before you enter.



Executive of the Year

Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies. This year’s winner will be the executive who has exhibited exemplary leadership throughout 12 months from June 1, 2017 to May 31, 2018.

This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities.

To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.

To enter this category, please answer the following:

  • Please give the name, company and position of the entrant, and the date of taking up this post.
  • What have been the entrant’s greatest achievements during the qualifying year? What has been the direct consequence of these on company performance?
  • How have these achievements strengthened the candidate’s influence within the industry? Please give examples.
  • What are the entrant’s greatest strengths as a leader? Please show how these have had a bearing on their achievements this year.
  • What specific previous accomplishments did the entrant have that made them perfectly fitted to achieving this success? For example, previous scientific or management experience.



Best Contract Research Organization – Full-Service Providers

The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.

This  award is split into two categories to separate the full-service providers from those smaller CROs that provide specialist services to their clients.

Today, the role of the CRO has gone beyond the traditional model of service-level agreements to offer bespoke clinical trial strategies and CROs are increasingly engaged in risk-sharing partnerships or acting as a single-source developer while also remaining committed to core strengths.

This Award for those companies who provide the full range of services to their clients will be judged on the quality of services and relationships they have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal.

To qualify, candidates must draw on their achievements in the year between June 1, 2017 and May 31, 2018.

To enter this category, please answer the following:

  • What particular capabilities and strengths does the CRO offer?
  • How has this firm delivered results that exceed sponsor expectations?
  • What innovations in patient recruitment strategy has the CRO brought to its partner?
  • How has it improved its performance, for example, in its quality of data, timelines and transparency?
  • What steps is the company taking towards streamlining data collection and reporting?



Best Contract Research Organization – Specialist Providers

The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.

This award is split into two categories to separate the full-service providers from those smaller CROs that provide specialists services to their clients.

This Award for those companies who provide specialist services to their clients will be judged on the quality of services and relationships they have built with their clients.

To qualify, candidates must draw on their achievements in the year between June 1, 2017 and May 31, 2018.

To enter this category, please answer the following:

  • What particular capabilities and strengths does the CRO offer?
  • How has this firm delivered results that exceed sponsor expectations?
  • What innovations has the CRO brought to its partner?
  • How has it improved its performance, for example, in its quality of data, timelines and transparency?
  • What steps is the company taking towards streamlining data collection and reporting?



WuXi AppTec's Biotech Company of the Year Award

The biotech industry’s entrepreneurial spirit and cutting-edge science are vital to the lifesciences industry and the research and development of medicines in the past few decades. This award honors outstanding achievement by biotech companies over the qualifying 12 months.

The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between June 1, 2017 and May 31, 2018. This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

To enter this category, please answer the following:

  • Name of entering company.
  • What has been the company’s most significant achievement during the year?
  • Give details of what the firm has accomplished over the year in terms of:
    – Bringing new products closer to their first markets
    – Raising funds
    – Signing significant licensing or partnership deals
    – Showing strong management not afraid of making hard decisions
    – Using proprietary science or technologies to address an unmet medical need
    – Successfully transforming the business from an early stage to a more mature company



Business Development Team of the Year

Scrip’s Business Development Team of the Year Award will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.

This Award will go to a team that is truly much more than the sum of its parts. The judges will be looking for strong performance across a number of criteria, such as achievement of short and long-term goals, and good communication of a shared vision.

To enter this category, please answer the following:

  • Please give details of the company(ies), the particular team being entered and its core function.
  • Please describe the team’s goals and vision, and how these are communicated.
  • What was the greatest achievement of the team during the year between June 1, 2017 and May 31, 2018 ?
  • Please describe how all parts of the team were fully aligned to achieve this, including how supporting functions, such as HR, finance and IT, were integrated into the team.
  • Rate the team, giving justification, according to the following criteria:
    - Achieving short-term and long-term goals
    - Managing resources
    - Providing a platform for professional development and teamwork
    - How does the team embody a management model that others should follow?



Syneos Health's Best New Drug Award

The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.

In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.
All recently launched new active substances, including small-molecules, biologicals or vaccines, are eligible to enter as long as they were first licensed in any market between June 1, 2017 and May 31, 2018. Generic and biosimilar products are not eligible for this award.

Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.

To enter this category, please answer the following:

  • Please give the trade and generic name of the entrant, the therapeutic indication for which it is being considered, and the company(ies) involved in its development (if more than one company, please detail the relationship between the parties).
  • What was the date and market of the candidate’s first approval and launch?
  • Please explain the mechanism of action of the candidate. How does this represent a step forward in treatment in this therapeutic area?
  • Please outline the evidence for the product’s clinical activity. How does its activity translate into a meaningful therapeutic benefit for patients, and how is this benefit over and above that provided by other treatments in this area?
  • How does the entrant address an unmet medical need?
  • What is the potential market size of the candidate?



Pharma Company of the Year Award

Scrip’s Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies over the qualifying 12 months, June 1, 2017 and May 31, 2018. This special award is chosen by Scrip's senior editorial team, based on a variety of key metrics:

  • Financial performance in 2017 compared with the previous year.
  • Strategic advances, looking at its most significant achievements over the year.
  • Progress in the emerging markets.
  • New product launches including line-extensions and formulations.
  • Advances in the drug pipeline, including major clinical trial reports.


Scrip’s Lifetime Achievement Award

The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career.

This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry. We welcome nominees for consideration for this award but the decision lies with Scrip's senior editorial team. The winner may be retired or semi-retired but will still be active in the industry in some capacity. 
Any nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

All nominations must include:

  • The name of the nominee.
  • The job title of the nominee (if applicable).
  • The company name (if applicable).
  • Your contact details.
  • The contact details of the nominee.
  • A précis of up to 1,500 words of why you think your nominee is worthy of receiving the Lifetime Achievement Award
 

 

Scrip Awards 2018

Scrip Awards 2018

For Sponsorship inquiries:

Christopher Keeling
Tel: +44 (20) 337 73183
Mobile: +44 (0) 7917 647 859
Email: christopher.keeling@informa.com

For all other inquiries:

Natalia Kay
Tel: +44 (0) 20 7017 5173
Mobile +44 (0) 7917 265 637
Email: Natalia.kay@informa.com